Effector regulatory t cells reflect the equilibrium between antitumor immunity and autoimmunity in adult t-cell leukemia

Cancer Immunology Research

Volumn 4, Issue 8, 2016, Pages 644-649

  Ureshino, Hiroshi ^a   Shindo, Takero ^a   Nishikawa, Hiroyoshi ^b   Watanabe, Nobukazu ^c   Watanabe, Eri ^c   Satoh, Natsuko ^c   Kitaura, Kazutaka ^d,e   Kitamura, Hiroaki ^a   Doi, Kazuko ^f   Nagase, Kotaro ^a   Kimura, Hiromi ^a   Samukawa, Makoto ^g   Kusunoki, Susumu ^g   Miyahara, Masaharu ^f   Shin I, Tadasu ^h   Suzuki, Ryuji ^d   Sakaguchi, Shimon ^b   Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^e Repertoire Genesis Incorporation   (Japan)

^f KARATSU RED CROSS HOSPITAL   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h BITS Company Limited   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTARABINE; GANGLIOSIDE GM2; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; METHOTREXATE; MOGAMULIZUMAB; PREDNISOLONE; STEROID; T LYMPHOCYTE RECEPTOR; BIOLOGICAL MARKER;

AGED; ALLERGIC ENCEPHALITIS; ANTITUMOR IMMUNITY; ARTICLE; AUTOIMMUNITY; BRAIN BIOPSY; CANCER IMMUNOTHERAPY; CASE REPORT; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CORTICOSTEROID THERAPY; DIPLOPIA; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; EFFECTOR CELL; EOSINOPHIL; HEARING IMPAIRMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LEUKEMIA RELAPSE; LONG TERM CARE; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC INFILTRATION; MALE; NEUROIMAGING; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN CEREBROSPINAL FLUID LEVEL; PTOSIS; RASH; REGULATORY T LYMPHOCYTE; SEQUENCE ANALYSIS; SKIN BIOPSY; T CELL DEPLETION; T CELL LEUKEMIA; TREATMENT RESPONSE; TUMOR IMMUNITY; BIOPSY; BRAIN; DIAGNOSTIC IMAGING; IMMUNITY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHENOTYPE; SKIN;

AGED; AUTOIMMUNITY; BIOMARKERS; BIOPSY; BRAIN; COMBINED MODALITY THERAPY; HUMANS; IMMUNITY; IMMUNOPHENOTYPING; LEUKEMIA-LYMPHOMA, ADULT T-CELL; MAGNETIC RESONANCE IMAGING; MALE; PHENOTYPE; SKIN; T-LYMPHOCYTES, REGULATORY;

EID: 84985918769     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0303     Document Type: Article

References (24)

1. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014;27:1-7.
2. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911.
3. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, et al. Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci U S A 2013;110:17945-50.
4. Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington WJr, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: A proposal from an international consensus meeting. J Clin Oncol 2009;27:453-9.
5. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: Clinical and hematologic features of 16 cases. Blood 1977; 50:481-92.
6. Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, et al. Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: Its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003;9:3625-34.
7. Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, et al. Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 2002; 99:1505-11.
8. Matsubara Y, Hori T, Morita R, Sakaguchi S, Uchiyama T. Delineation of immunoregulatory properties of adult T-cell leukemia cells. Int J Hematol 2006;84:63-9.
9. Shimauchi T, Kabashima K, Tokura Y. Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Sci 2008;99:98-106.
10. Kobayashi S, Nakano K, Watanabe E, Ishigaki T, Ohno N, Yuji K, et al. CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult t-cell leukemia/lymphoma. Clin Cancer Res 2014;20:2851-61.
11. Kobayashi S, Watanabe E, Ishigaki T, Ohno N, Yuji K, Nakano K, et al. Advanced human T-cell leukemia virus type 1 carriers and earlystage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. Cancer Sci 2015;106: 598-603.
12. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 2012;30:837-42.
13. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014;32:1157-63.
14. Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, et al. Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 2013;104:647-50.
15. Yoshie O, Matsushima K. CCR4 and its ligands: from bench to bedside. Int Immunol 2015;27:11-20.
16. Kitaura K, Fujii Y, Hayasaka D, Matsutani T, Shirai K, Nagata N, et al. High clonality of virus-specificT lymphocytes defined by TCRusagein the brains of mice infected with West Nile virus. J Immunol 2011;187:3919-30.
17. Chatila TA, Blaeser F, Ho N, Lederman HM, Voulgaropoulos C, Helms C, et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000;106: R75-81.
18. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-61.
19. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
20. Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006;66: 5716-22.
21. Arimoto K, Kadowaki N, Ishikawa T, Ichinohe T, Uchiyama T. FOXP3 expression in peripheral blood rapidly recovers and lacks correlation with the occurrence of graft-versus-host disease after allogeneic stem cell transplantation. Int J Hematol 2007;85:154-62.
22. Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, et al. Chronic graft-versus-host disease is associated with increased numbers of peripheral blood CD4+CD25high regulatory T cells. Blood 2004;103:2410-6.
23. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 2005;106: 2903-11.
24. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014;32:1020-30.